Cargando…

Hepatocellular Carcinoma: Portuguese Data in Chronic Hepatitis B Patients on Antiviral Therapy and Treatment Results With Sorafenib

Detalles Bibliográficos
Autor principal:	Simão, Adélia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Karger Publishers 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580183/ https://www.ncbi.nlm.nih.gov/pubmed/28868467 http://dx.doi.org/10.1016/j.jpge.2016.08.001

Ejemplares similares

Quantitative hepatitis B surface antigen predicts the antiviral response and hepatocellular carcinoma development in patients with chronic hepatitis B
por: Kim, Sung Eun
Publicado: (2017)

Direct-Acting Antiviral Therapy and Risk of Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C
por: Lee, Chang Hun, et al.
Publicado: (2021)

Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma
por: Han, Sojung, et al.
Publicado: (2020)

The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy
por: Varbobitis, Ioannis, et al.
Publicado: (2016)

Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation
por: Kim, Bo Hyun, et al.
Publicado: (2018)

Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Tsilimigras, Diamantis I., et al.
Publicado: (2020)

Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?
por: Kim, Do Young
Publicado: (2017)

How to compare antivirals in the treatment of chronic hepatitis B?
por: Ozaras, Resat, et al.
Publicado: (2009)

Aspirin, chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC)—will there ever be enough data?
por: Crane, Harry, et al.
Publicado: (2023)

Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis
por: Thiele, Maja, et al.
Publicado: (2013)

Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy
por: Alshuwaykh, Omar, et al.
Publicado: (2022)

Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Receiving Finite Periods of Antiviral Therapy
por: Lin, Chih-Lang, et al.
Publicado: (2023)

Occult hepatitis C infection identified in injection drug users with direct antiviral agents therapy and spontaneous resolution of hepatitis C virus infection
por: Silva, Eliane, et al.
Publicado: (2023)

Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment
por: Lee, I-Cheng, et al.
Publicado: (2022)

Does obesity increase the risk of hepatocellular carcinoma in chronic hepatitis B patients?
por: Jang, Byoung Kuk
Publicado: (2016)

Direct-acting antivirals trigger a favorable, sustained virological response in patients with chronic hepatitis C infections and hepatocellular carcinoma
por: Sohn, Won
Publicado: (2021)

A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib
por: Pietrobono, Silvia, et al.
Publicado: (2021)

Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study
por: Zhang, Yingqiang, et al.
Publicado: (2019)

Hepatitis B and C Viruses and Hepatocellular Carcinoma
por: Bartosch, Birke
Publicado: (2010)

Indefinite antiviral therapy may be required after surgical resection for hepatocellular carcinoma complicating chronic hepatitis B
por: Wei, Qiang, et al.
Publicado: (2013)

Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients
por: Wu, Xiaoning, et al.
Publicado: (2023)

Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype?
por: Shing, Kit, et al.
Publicado: (2020)

Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy
por: Ke, Yang, et al.
Publicado: (2013)

Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma
por: Zhao, Yang, et al.
Publicado: (2019)

Long-Term Prediction Model for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Antiviral Therapy: Based on Data from Korean Patients
por: Lee, Ji Hun, et al.
Publicado: (2022)

Is direct-acting antiviral treatment beneficial or harmful for patients with hepatitis C virus-related hepatocellular carcinoma?
por: Lee, Hye Won
Publicado: (2022)

Current Antiviral Therapy for Chronic Hepatitis B
por: Lim, Young-Suk, et al.
Publicado: (2004)

Antiviral therapy for chronic hepatitis B in China
por: Zheng, Xin, et al.
Publicado: (2014)

Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?
por: Chun, Ho Soo, et al.
Publicado: (2021)

Hepatocellular carcinomas: evolution to sorafenib resistance through hepatic leukaemia factor
por: Musso, Orlando, et al.
Publicado: (2019)

Low Incidence of Hepatocellular Carcinoma after Antiviral Therapy in Patients with Chronic Hepatitis C and Hemophilia
por: Kim, In Jung, et al.
Publicado: (2022)

Antiviral Therapy Reduces Mortality in Hepatocellular Carcinoma Patients with Low-Level Hepatitis B Viremia
por: Wang, Xinhui, et al.
Publicado: (2021)

The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma
por: Wu, Fei-Xiang, et al.
Publicado: (2017)

Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib
por: Kuo, Yuan-Hung, et al.
Publicado: (2022)

How Durable Is Functional Cure (Hepatitis B Surface Antigen Loss) in Patients With Chronic Hepatitis B Treated With Current Antivirals?
por: Loglio, Alessandro, et al.
Publicado: (2020)

Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact
por: Yip, Terry Cheuk-Fung, et al.
Publicado: (2021)

Predicting the risk of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy: Validating the CAMD and AASL scores in China
por: Wang, Shuai, et al.
Publicado: (2022)

Durability of antiviral therapy for chronic hepatitis C after achieving sustained virological response
por: Heo, Jeong
Publicado: (2011)

What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
por: Kim, Jin-Wook
Publicado: (2019)

Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus-Related Hepatocellular Carcinoma After Partial Hepatectomy
por: Dong, Wei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qvu5c26au6b1tspjisj1qu4r3d